FORT WORTH, Texas, Nov. 20 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM), announced today a published case demonstrating the efficacy of their advanced wound care collagen product, CellerateRx(R). The case was presented in the November/December 2008 issue of Podiatry Management in the special section, Diabetic Wound Care Management on the Leading Edge: Case Presentations from APWCA, APWCA Case #1: Using Combined Treatment Modalities for Successful Wound Healing. The case was by Jane Fore, MD, a board certified internist and certified wound care specialist, whose practice is totally dedicated to the healing of challenging wounds.
"We are very excited about the unsolicited case published in this month's edition of Podiatry Management," states Cathy Bradshaw, President of Wound Care Innovations. "Diabetic foot wounds with infections can be complicated and can require multiple approaches to treatment. This case demonstrates the biocompatibility of CellerateRx(R) in supporting the successful take of living skin equivalents and the delivery of antimicrobials when used in combinational therapies. The article further reports CellerateRx's(R) effectiveness in treating tunneling wounds, and is easy to use. Packing and unpacking these tunneling wounds can be very painful for the patient. CellerateRx(R) is biodegradable and does not need to be removed from the wound. We are delighted to be able to provide to the market a unique, patented advanced wound care collagen product to assist in the management of these difficult wounds."
Diabetic wounds are problematic for patients and a drain on the healthcare industry. In the United States, it is estimated that 15-20% of diabetics will develop a foot ulcer in their lifetime and that 14-24% of these ulcers will result in amputations. Every 30 seconds a leg is lost to diabetes somewhere in the world.
CellerateRx(R) is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It comes in two forms, a powder which is about 95% collagen, and a gel which is about 65% collagen, and contains no additives or synthetics. CellerateRx(R) is manufactured in the United States.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information: Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Corporate Secretary 954-315-9242 817-820-7080
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved